Saturday 17 October 2026
Export RAPP’s income statement to Excel — free account
Rapport Therapeutics, Inc.
RAPP Healthcare Biotechnology
In the quarter to June 2026, EPS fell 58.7% and free cash flow fell 64.8%, each against the same quarter a year earlier.
27.57
2.00
−6.76%
Follow RAPP
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 16.55 | 6.43 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 29.74 | 42.27 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 26 | 69 | 84 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | (11) | (35) | (78) | (111) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | (11) | (35) | (78) | (111) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | (2) | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (13.71) | (23.10) | (3.78) | (2.86) | |||||
| Cash flow | — | — | — | — | — | — | (4.17) | (18.05) | (3.13) | (2.25) | |||||
| Capex | — | — | — | — | — | — | (6.80) | (1.09) | (0.12) | (0.02) | |||||
| Free cash flow | — | — | — | — | — | — | (10.97) | (19.13) | (3.24) | (2.26) | |||||
| Book value | — | — | — | — | — | — | 25.10 | 93.59 | 14.73 | 12.45 | |||||
| Shares, m | — | — | — | — | — | — | 1 | 2 | 21 | 39 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (3) | (27) | (65) | (87) | ||||
| Capex | — | — | — | — | — | — | (5) | (2) | (2) | (1) | |||||
| Free cash flow | — | — | — | — | — | — | (9) | (29) | (67) | (88) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 30 | 142 | 301 | 480 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | (31) | (148) | (305) | (491) | |||||
| Shareholders’ equity | — | — | — | — | — | — | 20 | 141 | 305 | 485 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (37.20) | (33.30) | (26.95) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | (123,593.75) | 0.00 | |||||
| ROE | — | — | — | — | — | — | 0.00 | 194.90 | (55.97) | (28.22) | |||||
Negative figures in brackets.
Latest quarter Mar 2026
Charts ten years each
Rapport Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ABSI Absci Corporation | $1.5B | — (loss-making) | — (loss-making) | −46.37% (below 0%: shrinking) | n/m | −71.74% (below 0%: shrinking) | 100.00% | (10,741.51%) | Compare |
| IMCR Immunocore Holdings PLC Sponsored ADR | $1.5B | — (loss-making) | 208× | +18.34% (above 0%: growing) | n/m | −40.74% (below 0%: shrinking) | 99.06% | (2.58%) | Compare |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | — (loss-making) | — (loss-making) | +28.14% (above 0%: growing) | n/m | +12.50% (above 0%: growing) | 84.11% | (35.05%) | Compare |
| ANAB AnaptysBio, Inc. | $1.5B | — (loss-making) | 220× | −7.98% (below 0%: shrinking) | n/m | −141.60% (below 0%: shrinking) | 100.00% | (135.53%) | Compare |
| RAPP Rapport Therapeutics, Inc. | $1.4B | — (loss-making) | — | — | n/m | −64.75% (below 0%: shrinking) | 100.00% | 0.00% | |
| AAPG Ascentage Pharma Group International - Unsponsored ADR | $1.4B | — | — | — | — | +17.74% (above 0%: growing) | — | — | Compare |
| OMER Omeros Corporation | $1.4B | 9.5× | 2.1× | +35.46% (above 0%: growing) | n/m | +118.70% (above 0%: growing) | 97.20% | 0.26% | Compare |
| INBX Inhibrx Biosciences, Inc. | $1.3B | — (loss-making) | — (loss-making) | +992.44% (above 0%: growing) | n/m | +0.12% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ORIC Oric Pharmaceuticals, Inc. | $1.3B | — (loss-making) | — | — | n/m | −3.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $1.4B | — | 208× | +23.24% | — | −1.65% | 99.06% | (2.58%) |
Rapport Therapeutics, Inc. (RAPP) key facts
- Rapport Therapeutics, Inc. (RAPP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, RAPP traded at $27.57, a market capitalization of $1.4 billion.
- Return on equity was −28.2% and debt-to-equity 0.00.